Enliven Therapeutics CMO Helen Louise Collins disposes of USD 262,213 in common shares - ELVN News | RalliesEnliven Therapeutics CMO Helen Louise Collins disposes of USD 262,213 in common shares
E
ELVN• Insider share sale and option exercise
- Enliven Therapeutics Chief Medical Officer Helen Louise Collins exercised stock options for 5,000 shares at $2.48 on July 17, 2026.
- Collins sold 5,000 shares in multiple transactions at prices ranging from $49.72 to $53.93.
- Beneficial ownership following the transactions: 25,000 shares of common stock.
- Derivative holdings following the transactions: 116,268 stock options with a $2.48 exercise price, expiring June 17, 2031.
KIDZ
•
